Mahta Alimadadi

Mahta Alimadadi

Auto-generated profile, based on publicly available information

Mahta Alimadadi

Department of Clinical Pharmacy, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2025 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
YRYekta Rameshi
Yekta Rameshi
SDSimin Dashti‐Khavidaki
Simin Dashti‐Khavidaki
SRSoghra Rabizadeh
Soghra Rabizadeh
MAMahta Alimadadi
Mahta Alimadadi
AMAlimohammad Moradi
Alimohammad Moradi
ZAZahra Ahmadinejad
Zahra Ahmadinejad
Introduction: Liver transplantation is associated with various metabolic disorders. Peri‐transplant hyperglycemia is among the most frequent metabolic disorders among liver transplant recipients. Hyperglycemia following liver transplantation can increase the risk of post‐transplant complications, potentially impacting both graft and recipient outcomes. Several studies have compared intensive with standard blood glucose control strategies in liver transplant recipients. However, a comprehensive protocol for managing peri‐transplant hyperglycemia remains elusive. This review aimed to synthesise existing literature on the mechanisms, associated factors, and consequences of hyperglycemia after liver transplantation, and to provide recommendations for managing hyperglycemia in this patient population. Method: PubMed, Scopus, and UpToDate databases and American Diabetes Association guidelines were searched without time limitations until February 2025. Results: Peri‐liver transplant hyperglycemia can be attributed to several factors, including post‐reperfusion hepatocyte injury, insulin resistance stemming from underlying liver disease, surgical stress, and the use of immunosuppressive drugs. Various factors associated with peri‐transplant hyperglycemia can be categorised into pre‐transplant recipient factors, intraoperative factors, and donor‐related factors. Research has shown that inadequate glycemic control during the peri‐transplant period may have detrimental effects on post‐transplant outcomes, including an increased incidence of infections, graft rejection, acute kidney injury, prolonged hospital stays, and higher overall mortality. Conclusion: The suggestions presented in this article, which consider the recipient's medical history and clinical conditions, can serve as a framework for healthcare providers to manage peri‐liver transplant hyperglycemia effectively.

1 January 2025 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
BSBita Shahrami
Bita Shahrami
MAMahta Alimadadi
Mahta Alimadadi
SRSoma Rahimi
Soma Rahimi
MAMona Abutalebzadeh
Mona Abutalebzadeh
STSoheila Tayefeh
Soheila Tayefeh
EHElham Hadidi
Elham Hadidi
Background: Occupational health programs play a critical role in maintaining employee well‐being, particularly for healthcare workers exposed to unique risks. Clinical pharmacists are well‐positioned to address drug‐related problems (DRPs) in these settings, yet their role in occupational health remains underexplored. This study assesses the frequency and resolution of DRPs following clinical pharmacist interventions among pharmacy staff in an occupational health setting. Methods: This experimental study was conducted at the 13‐Aban Pharmacotherapy Clinic of Tehran University of Medical Sciences, Tehran, Iran. Pharmacy staff with chronic diseases or abnormal test results was identified based on medical records. A single clinical pharmacist reviewed DRPs using the DOCUMENT classification system, provided interventions, and followed up. Recommendations were made directly to participants, and adherence to these recommendations was assessed. Data were analyzed using descriptive statistics and correlation tests. Results: Among 601 medical records reviewed, 239 participants met inclusion criteria, and 139 attended pharmacotherapy visits. A total of 277 DRPs were identified, averaging 1.99 DRPs per participant. The most common DRPs were the need for preventative therapy (37.2%), untreated conditions (15.9%), and laboratory monitoring (14.8%). A total of 443 recommendations were provided to participants, with an adherence rate of 76.4%. Among those who fully adhered to the recommendations, 97.2% of DRPs were resolved. While adherence was initially higher among female participants, overall compliance rates did not significantly differ by gender. Conclusion: Clinical pharmacist interventions effectively identified and resolved DRPs among pharmacy staff, improving medication management. These findings highlight the value of integrating clinical pharmacists into occupational health programs to enhance medication safety and adherence.